Stockreport

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics, Inc.  (KYMR) 
PDF KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IR [Read more]